Abstract
We aim to confirm previous observations among postmenopausal osteoporotic women who received denosumab in terms of densitometric changes. We performed an observational clinical practice scenario study assessing baseline bone mineral density and its change after 2 years of treatment in postmenopausal osteoporotic women. Most of our patients were severe and had previous fracture and had received several treatments before denosumab initiation. We observed a 10.06% (± 3.46) improvement in spine, and a 4.87% (± 4.78) improvement in femoral neck. Our findings are in accordance with other authors that suggest denosumab provides densitometric gain in clinical practice in severe postmenopausal osteoporotic women.
This is a preview of subscription content, log in via an institution to check access.
References
Laroche M, Baradat C, Ruyssen-Witrand A, Degboe Y (2018) Variability of denosumab densitometric response in postmenopausal osteoporosis. Rheumatol Int 38:461–466
Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S et al (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al, FREEDOM Trial (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161
Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T et al (2017) The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab 35:91–98
Torrente-Segarra V, Roig Vilaseca D, Reina D, Cerdà D, Navarro V, Estrada P et al (2016) Evaluación de la eficacia y seguridad de denosumab en osteoporosis en práctica clínica en una consulta de Reumatología. Reumatol Clin 12(Espec Cong):27–254
Author information
Authors and Affiliations
Corresponding author
Additional information
This comment refers to the article available at https://doi.org/10.1007/s00296-018-3929-0.
Rights and permissions
About this article
Cite this article
Torrente-Segarra, V., Roig-Vilaseca, D. Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on “Variability of denosumab densitometric response in postmenopausal osteoporosis”. Rheumatol Int 38, 1161–1162 (2018). https://doi.org/10.1007/s00296-018-4007-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-018-4007-3